MXPA04005306A - Benzoxazoles substituidos y analogos como agentes estrogenicos. - Google Patents

Benzoxazoles substituidos y analogos como agentes estrogenicos.

Info

Publication number
MXPA04005306A
MXPA04005306A MXPA04005306A MXPA04005306A MXPA04005306A MX PA04005306 A MXPA04005306 A MX PA04005306A MX PA04005306 A MXPA04005306 A MX PA04005306A MX PA04005306 A MXPA04005306 A MX PA04005306A MX PA04005306 A MXPA04005306 A MX PA04005306A
Authority
MX
Mexico
Prior art keywords
analogues
estrogenic agents
substituted benzoxazoles
benzoxazoles
substituted
Prior art date
Application number
MXPA04005306A
Other languages
English (en)
Inventor
Richard Lyttle Cecil
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA04005306A publication Critical patent/MXPA04005306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)

Abstract

La presente invencion proporciona moduladores del receptor de estrogeno de la formula (i), que tienen la estructura de la formula (i) en donde R1, R2, R3, R3A, y R4, Y X son como se definieron el a especificacion, o una sal de los mismos farmaceuticamente aceptable.(ver formula I).
MXPA04005306A 2001-12-05 2002-12-03 Benzoxazoles substituidos y analogos como agentes estrogenicos. MXPA04005306A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33666301P 2001-12-05 2001-12-05
PCT/US2002/038513 WO2003050095A1 (en) 2001-12-05 2002-12-03 Substituted benzoxazoles and analogues as estrogenic agents

Publications (1)

Publication Number Publication Date
MXPA04005306A true MXPA04005306A (es) 2004-09-13

Family

ID=23317104

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005306A MXPA04005306A (es) 2001-12-05 2002-12-03 Benzoxazoles substituidos y analogos como agentes estrogenicos.

Country Status (24)

Country Link
US (4) US6794403B2 (es)
EP (2) EP1451165A1 (es)
JP (2) JP4689960B2 (es)
KR (1) KR20050044717A (es)
CN (2) CN100443477C (es)
AR (1) AR037745A1 (es)
AU (2) AU2002353014A1 (es)
BR (1) BR0214767A (es)
CA (1) CA2467517C (es)
CO (1) CO5580830A2 (es)
EC (1) ECSP045133A (es)
HU (1) HUP0500010A2 (es)
IL (1) IL162256A0 (es)
IN (1) IN2005KO00272A (es)
MX (1) MXPA04005306A (es)
NO (1) NO20042811L (es)
NZ (1) NZ560878A (es)
PL (1) PL370771A1 (es)
RU (2) RU2330847C2 (es)
SG (1) SG165987A1 (es)
TW (1) TW200304822A (es)
UA (1) UA83620C2 (es)
WO (1) WO2003050095A1 (es)
ZA (1) ZA200405249B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531850A (en) 2001-11-19 2007-01-26 Lilly Co Eli Substituted benzopyrans as selective estrogen receptor-beta agonists
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
DE60323155D1 (de) * 2002-12-19 2008-10-02 Scripps Research Inst Von transthyretin und zur hemmung von transthyretin-fehlfaltung
SI1626974T1 (sl) * 2003-04-21 2009-02-28 Lilly Co Eli Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
TW200500065A (en) * 2003-05-21 2005-01-01 Wyeth Corp Antiarthritic combinations
US20080319175A1 (en) 2004-05-20 2008-12-25 The Scripps Research Institute Transthyretin Stabilization
EP1761513A1 (en) * 2004-07-01 2007-03-14 Wyeth Tetracyclic compounds as estrogen ligands
BRPI0514628A (pt) * 2004-08-26 2008-06-17 Wyeth Corp composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou inibir doenças, métodos para baixar os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl; ou inibir avaria da parede vascular, para prover aumento de cognição ou neuroproteção; para tratar ou inibir estados doentios induzidos por radical livre, condições, e inchação ou erosão de junta; ou tratar ou inibir avaria de junta secundária a procedimentos artroscópicos ou cirúrgicos, e, composição farmacêutica
MX2007002624A (es) * 2004-09-02 2007-04-27 Wyeth Corp Fenoles de fenantridina carbonilo como moduladores de citocina.
RU2007106870A (ru) 2004-09-07 2008-10-20 Вайет (Us) 6Н-[1]БЕНЗОПИРАНО[4,3-b]ХИНОЛИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЭСТРОГЕННЫХ АГЕНТОВ
BRPI0518789A2 (pt) * 2004-12-02 2008-12-09 Wyeth Corp formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
CA2589103A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
US20060121110A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
RU2007120254A (ru) * 2004-12-17 2009-01-27 Вайет (Us) Новые способы применения агонистов эстрогена бета
WO2006088716A1 (en) * 2005-02-15 2006-08-24 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
US20060211672A1 (en) * 2005-02-16 2006-09-21 Wyeth Use of estrogen receptor-beta selective agonists for radiation-or chemotherapy-induced mucositis and radiation cystitis
TW200643018A (en) * 2005-03-07 2006-12-16 Wyeth Corp Process for the preparation of substituted benzoxazole compounds
EP1856068A1 (en) * 2005-03-07 2007-11-21 Wyeth, A Corporation of the State of Delaware Process for the purification of substituted benzoxazole compounds
JP2008533012A (ja) * 2005-03-08 2008-08-21 ワイス ２−（３−フルオロ−４−ヒドロキシフェニル）−７−ビニル−１，３−ベンゾキサゾール−５−オールの結晶形成およびエストロゲンレセプターモジュレーターとしてのその使用
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
TW200800177A (en) * 2006-02-14 2008-01-01 Wyeth Corp Aqueous pharmaceutical formulations of ERβ selective ligands
WO2007103873A2 (en) * 2006-03-06 2007-09-13 Wyeth Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20070207202A1 (en) * 2006-03-06 2007-09-06 Wyeth Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
PE20071019A1 (es) * 2006-03-06 2007-10-29 Wyeth Corp Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos
CA2643015A1 (en) * 2006-03-06 2007-09-13 Wyeth Tablet formulations and processes
JP4986485B2 (ja) * 2006-03-28 2012-07-25 株式会社Ａｄｅｋａ エポキシ樹脂硬化性組成物
EP2074223A4 (en) * 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080176914A1 (en) * 2006-11-21 2008-07-24 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080139633A1 (en) * 2006-11-21 2008-06-12 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080132554A1 (en) * 2006-11-21 2008-06-05 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
WO2008064217A2 (en) * 2006-11-21 2008-05-29 Wyeth Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof
US20090239920A1 (en) * 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080146630A1 (en) * 2006-11-21 2008-06-19 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EA201692214A1 (ru) 2007-01-22 2017-11-30 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
PE20081699A1 (es) * 2007-01-31 2008-12-31 Wyeth Corp DERIVADOS DE HIDROXIFENILO COMO LIGANDOS SELECTIVOS DE ERß
US20080194533A1 (en) * 2007-02-09 2008-08-14 Wyeth Process for selective sulfation of aromatic hydroxyl groups
US20080275073A1 (en) * 2007-04-20 2008-11-06 Wyeth Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts
US20080262009A1 (en) * 2007-04-20 2008-10-23 Wyeth Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts
US20080262008A1 (en) * 2007-04-20 2008-10-23 Wyeth Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts
US20080262010A1 (en) * 2007-04-20 2008-10-23 Wyeth Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts
WO2009009417A2 (en) * 2007-07-06 2009-01-15 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
US20110212923A1 (en) * 2008-02-08 2011-09-01 Pfizer Inc. Phosphate Derivatives of Substituted Benzoxazoles
BRPI0919816A2 (pt) * 2008-09-26 2019-09-24 Eisai R&D Man Co Ltd uso compostos benzoxazólicos no tratamento de malária
US8354400B2 (en) 2008-09-26 2013-01-15 Eisai R&D Co., Ltd. Benzoxazole compounds and methods of use
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2011014516A1 (en) 2009-07-28 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Estrogen antagonists as treatments for sclerosing disorders
WO2012044830A1 (en) * 2010-10-01 2012-04-05 Indiana University Research And Technology Corporation Treatment of symptoms associated with menopause
US8865754B2 (en) * 2011-03-03 2014-10-21 Proteotech Inc. Compounds for the treatment of neurodegenerative diseases
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
JP6060263B2 (ja) * 2012-12-27 2017-01-11 住友化学株式会社 縮合オキサゾール化合物及びその有害生物防除用途
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
EP2948436A4 (en) 2013-01-25 2016-07-13 Aldeyra Therapeutics Inc NOVEL CASES IN THE TREATMENT OF MACULAR GENERATION
WO2016021706A1 (ja) * 2014-08-08 2016-02-11 カズマパートナーズ株式会社 縮合複素環化合物
EP3782616B1 (en) 2014-09-02 2023-11-01 The Regents of The University of California Estrogen receptor ligand treatment for neurodegenerative diseases
CN104974103A (zh) * 2015-07-14 2015-10-14 佛山市赛维斯医药科技有限公司 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途
CN104926745A (zh) * 2015-07-14 2015-09-23 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途
JP6947406B2 (ja) 2015-08-21 2021-10-13 アルデイラ セラピューティクス， インコーポレイテッド 重水素化化合物およびその使用
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
CN108586374B (zh) * 2018-01-12 2021-01-05 浙江鼎龙科技有限公司 2-苯基苯并噁唑类化合物的制备方法
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CN111467341B (zh) * 2020-04-24 2021-05-11 山东师范大学 3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
CN114805112A (zh) * 2022-05-31 2022-07-29 常州大学 一种pde2抑制剂酰胺类衍生物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1435721A (en) * 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
GB1590587A (en) 1977-06-28 1981-06-03 Lilly Industries Ltd Benoxaprofen
CZ104795A3 (en) * 1994-04-29 1996-02-14 Lilly Co Eli Benzimidazole derivative, process of its preparation, its use for preparing a pharmaceutical preparation and the pharmaceutical composition containing thereof
KR100263137B1 (ko) 1995-09-08 2000-08-01 오테스코그 페르 오판 수용체
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5948776A (en) * 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US5919808A (en) * 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US7157568B1 (en) 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
DE59905847D1 (de) 1998-05-05 2003-07-10 Altana Pharma Ag Benzimidazole und oxazole
GB9814620D0 (en) 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
AU761647B2 (en) 1998-07-06 2003-06-05 Altana Pharma Ag New benzoxazoles with PDE-inhibiting activity
AU1199600A (en) 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
EP1131336B1 (en) 1998-11-20 2002-08-28 Akzo Nobel N.V. Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
PT1140889E (pt) 1998-12-30 2004-01-30 Signal Pharm Inc Compostos e metodos para modulacao de receptores de estrogenio
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6358943B1 (en) * 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
US6436923B1 (en) * 1999-03-17 2002-08-20 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2000059897A2 (en) 1999-04-06 2000-10-12 Akzo Nobel N.V. Esters and carbonates of 2-(4-hydroxyphenyl)-6(or 5)-hydroxy-benzothiophene derivatives as selective estrogenic compounds
DK1165184T3 (da) 1999-04-09 2004-04-13 Karobio Ab Estrogenreceptor-beta antagonisme og knoglesygdomme
TR200102992T2 (tr) * 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
GB9913649D0 (en) 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
AU784200B2 (en) 2000-02-14 2006-02-23 Merck Sharp & Dohme Corp. Estrogen receptor modulators
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
US6559177B2 (en) * 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
BRPI0514628A (pt) * 2004-08-26 2008-06-17 Wyeth Corp composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou inibir doenças, métodos para baixar os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl; ou inibir avaria da parede vascular, para prover aumento de cognição ou neuroproteção; para tratar ou inibir estados doentios induzidos por radical livre, condições, e inchação ou erosão de junta; ou tratar ou inibir avaria de junta secundária a procedimentos artroscópicos ou cirúrgicos, e, composição farmacêutica

Also Published As

Publication number Publication date
IN2005KO00272A (es) 2015-08-07
PL370771A1 (en) 2005-05-30
US20050080117A1 (en) 2005-04-14
EP1451165A1 (en) 2004-09-01
CA2467517C (en) 2011-05-03
US20030199562A1 (en) 2003-10-23
US20070167503A1 (en) 2007-07-19
SG165987A1 (en) 2010-11-29
KR20050044717A (ko) 2005-05-12
JP2011052010A (ja) 2011-03-17
ECSP045133A (es) 2004-07-23
US7148247B2 (en) 2006-12-12
JP2005520794A (ja) 2005-07-14
NZ560878A (en) 2009-03-31
AU2009210357A1 (en) 2009-09-10
AU2002353014A1 (en) 2003-06-23
CO5580830A2 (es) 2005-11-30
ZA200405249B (en) 2007-01-31
BR0214767A (pt) 2004-11-09
RU2008107295A (ru) 2009-09-10
WO2003050095A1 (en) 2003-06-19
AR037745A1 (es) 2004-12-01
US6794403B2 (en) 2004-09-21
UA83620C2 (ru) 2008-08-11
NO20042811L (no) 2004-07-05
RU2004120283A (ru) 2005-03-27
CN101423500A (zh) 2009-05-06
EP1982713A3 (en) 2009-03-25
US7129258B2 (en) 2006-10-31
CN100443477C (zh) 2008-12-17
CN1646504A (zh) 2005-07-27
US20050239851A1 (en) 2005-10-27
JP4689960B2 (ja) 2011-06-01
US7531564B2 (en) 2009-05-12
TW200304822A (en) 2003-10-16
IL162256A0 (en) 2005-11-20
RU2330847C2 (ru) 2008-08-10
CA2467517A1 (en) 2003-06-19
EP1982713A2 (en) 2008-10-22
HUP0500010A2 (hu) 2005-04-28

Similar Documents

Publication Publication Date Title
SG165987A1 (en) Substituted benzoxazoles and analogues as estrogenic agents
MXPA06001592A (es) Derivados de (4-hidroxifenil)-1h-indol-3-carbaldehido oxima como agentes estrogenicos.
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
WO2003051805A3 (en) Substituted phenyl naphthalenes as estrogenic agents
MXPA05012249A (es) Derivados de arilcarbaldehido oxima y su uso como agentes estrogenicos.
MXPA05011679A (es) Derivados de hidroxibifenilcarbaldehido oxima y su uso como agentes estrogenicos.
TW200510319A (en) Phenyl quinolines and their use as estrogenic agents
EP1040823A3 (en) Stable foam compositions
MXPA04005784A (es) 2-fenilbenzofuranos sustituidos como agentes estrogenitos.
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
YU12203A (sh) Novi derivati fenilalanina
BG106586A (en) Pyrazolopyramidines as therapeutic agents
HK1049284A1 (en) Benzimidazole compounds having nociceptin receptoraffinity
HK1071059A1 (en) Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
MXPA02009706A (es) Metodo para sintesis de perindopril y sus sales farmaceuticamente aceptables.
AU2003239389A1 (en) Opioid receptor antagonists
AU2001266575A1 (en) Chemical compounds
MY138826A (en) 2,7-substituted indoles
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
BR0314844A (pt) Novo composto
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
WO2000007544A3 (en) Vitronectin receptor antagonists
AU7962000A (en) Us0027324for eating disorders
AU2002322433A1 (en) N,n-dinitramide salts as solubilizing agents for biologically active agents

Legal Events

Date Code Title Description
FG Grant or registration